

MAV+ Senegal

Last updated: February 2025

Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+) is a comprehensive support package tackling barriers to manufacturing and access to health products and technologies in Africa. MAV+ is tightly aligned with African strategies and is supported by a broad and inclusive consortium of European actors.

Senegal is well-positioned to become a regional and continental vaccine hub with the production of yellow fever and other vaccines in ECOWAS. It is also the first producer of these vaccines in francophone Africa. In 2021, following a LAB Pharma organized by Senegal (Bureau Operationnel de Suivi) with support of Belgium and UNIDO, Senegal established a national recovery plan for the pharmaceutical sector, which is estimated to cost €500 million.

MAV+ focuses on:

- Providing direct investment in local production
- Supporting the new national regulatory authority
- The coordination, management and implementation of the national plan through grants, loans and technical assistance as well as collaboration with the Ministry of Health's Delivery Unit

MAV+ also supports skills development (technical and vocational education and training as well as academic training), R&D and digitalisation.

Key MAV+ collaborations and activities

Direct investments in local production

MAV+ investments support the construction of Senegal flagship industrial project: the new MADIBA vaccine production site, hosted by the Institute Pasteur of Dakar (IPD). MAV+ is also funding the construction of a new yellow fever vaccine production facility at the IPD. This facility, the only one of its kind in Africa, will double IPD's vaccine production capacity, enabling it to meet the demands of vaccination campaigns. MAV+ also supports non-vaccine producers.

Supporting the new regulatory body

Team Europe supported Senegal to create in 2022 the national regulatory authority, "l'Agence sénégalaise de Réglementation Pharmaceutique" and provided technical and financial support to the national regulatory authority in its successful effort to reach WHO Global Benchmarking Tool Maturity Level 3 in December 2024. Team Europe also supports regulatory harmonization between Senegal and the West African Economic and Monetary Union (UEMOA) and the African Medicines Regulatory Harmonization (AMRH) programme.



Fast-tracking pharmaceutical sector reforms

Team Europe is providing long-term technical assistance to Senegal's Ministry of Health to support the management and coordination of the national recovery plan for the pharmaceutical sector (support to the Delivery Unit).

Team Europe is also supporting the implementation of the national plan through a blended approach: a €5 million grant (announced in December 2022) for the MADIBA/IPD project, combined with a €25 million Policy-Based Loan (PBL) from AFD (announced mid-2022) and a €20 million grant from KfW (announced in July 2023) for system-wide reforms.

The Special Measure 2023 will support the enabling environment for local production of health products with a focus on governance; skills development through elaboration and implementation of TVET and higher education curricula for biomanufacturing, regulatory and clinical trials needs; R&D; support for the private sector; supply chain strengthening (digitalization); and the regulatory environment.

Team Europe funders

MAV+ actions in Senegal are primarily funded by the European Commission, the European Investment Bank (EIB), Belgium, France and Germany. Germany also funds multi-country projects that include Senegal.

Partners

IPD (Institute Pasteur of Dakar); Senegal Ministry of Economy, Planning and Cooperation; Senegal Ministry of Tertiary Education, Research and Innovation; Senegal Ministry of Health and Social Action; Senegal Ministry of Industry and Commerce; Senegal Ministry of Professional Training; Association Sénégalaise de l'Industrie Pharmaceutique; and Senegal's National Regulatory Authority (Agence sénégalaise de Réglementation Pharmaceutique (ARP)). ARP is the key partner for multi-country projects.

Additional Team Europe and international stakeholders

Stakeholders for national projects include AFD (French Development Agency), Enabel, Expertise France, GIZ and KfW; multi-country project stakeholders include the German Federal Institute for Drugs and Paul-Erlich-Institut (PEI), Sciensano and Belgium Federal Agency for Medicines and Health Products (FAMHP).